Possible scenario
Rapid AI Adoption
38% Chance
HHS and FDA move quickly from announcement to implementation, positioning AI-generated trial simulations, synthetic controls, and adaptive protocol tools as acceptable evidence-support mechanisms. Large pharma and AI-native biotech firms increase spending on validated AI trial platforms, while traditional trial-service vendors face margin pressure.
Secondary impacts
- Healthcare +1.6%
- Technology +1.1%
- Business Services -0.1%
Tickers
- RXRX+6.1%
- TEM+5.6%
- SDGR+3.3%
- -1.6%
Portfolio impact
S&P 500+0.6%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.